Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

71 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Two-year follow-up after endobronchial coil treatment in emphysema: results from the REVOLENS study.
Deslée G, Leroy S, Perotin JM, Mal H, Dutau H, Bourdin A, Vergnon JM, Pison C, Kessler R, Jounieaux V, Salaün M, Marceau A, Dury S, Benzaquen J, Bonnaire M, Dukic S, Barbe C, Marquette CH; , on behalf of the REVOLENS Study Group13; REVOLENS Study Group. Deslée G, et al. Among authors: dukic s. Eur Respir J. 2017 Dec 21;50(6):1701740. doi: 10.1183/13993003.01740-2017. Print 2017 Dec. Eur Respir J. 2017. PMID: 29269583 Free article. Clinical Trial. No abstract available.
Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe Emphysema: The REVOLENS Randomized Clinical Trial.
Deslée G, Mal H, Dutau H, Bourdin A, Vergnon JM, Pison C, Kessler R, Jounieaux V, Thiberville L, Leroy S, Marceau A, Laroumagne S, Mallet JP, Dukic S, Barbe C, Bulsei J, Jolly D, Durand-Zaleski I, Marquette CH; REVOLENS Study Group. Deslée G, et al. Among authors: dukic s. JAMA. 2016 Jan 12;315(2):175-84. doi: 10.1001/jama.2015.17821. JAMA. 2016. PMID: 26757466 Free article. Clinical Trial.
Cost-effectiveness of lung volume reduction coil treatment in patients with severe emphysema: results from the 2-year follow-up crossover REVOLENS study (REVOLENS-2 study).
Bulsei J, Leroy S, Perotin JM, Mal H, Marquette CH, Dutau H, Bourdin A, Vergnon JM, Pison C, Kessler R, Jounieaux V, Salaün M, Marceau A, Dukic S, Barbe C, Bonnaire M, Deslee G, Durand-Zaleski I; REVOLENS study group. Bulsei J, et al. Among authors: dukic s. Respir Res. 2018 May 9;19(1):84. doi: 10.1186/s12931-018-0796-x. Respir Res. 2018. PMID: 29743071 Free PMC article. Clinical Trial.
Association between proton pump inhibitors and severe hematological toxicity in patients receiving pemetrexed-based anticancer treatment: The prospective IPPEM study.
Slimano F, Le Bozec A, Cransac A, Foucher P, Lesauvage F, Delclaux B, Dory A, Mennecier B, Bertrand B, Gubeno-Dumon MC, Dukic S, Mongaret C, Bouché O, Hettler D, Boulin M, Dewolf M, Kanagaratnam L. Slimano F, et al. Among authors: dukic s. Lung Cancer. 2022 Apr;166:114-121. doi: 10.1016/j.lungcan.2022.02.007. Epub 2022 Feb 24. Lung Cancer. 2022. PMID: 35263663
Conformation-dependent binding of a Tetrastatin peptide to αvβ3 integrin decreases melanoma progression through FAK/PI3K/Akt pathway inhibition.
Lambert E, Fuselier E, Ramont L, Brassart B, Dukic S, Oudart JB, Dupont-Deshorgue A, Sellier C, Machado C, Dauchez M, Monboisse JC, Maquart FX, Baud S, Brassart-Pasco S. Lambert E, et al. Among authors: dukic s. Sci Rep. 2018 Jun 29;8(1):9837. doi: 10.1038/s41598-018-28003-x. Sci Rep. 2018. PMID: 29959360 Free PMC article.
Structural characterization and in vivo pro-tumor properties of a highly conserved matrikine.
Da Silva J, Lameiras P, Beljebbar A, Berquand A, Villemin M, Ramont L, Dukic S, Nuzillard JM, Molinari M, Gautier M, Brassart-Pasco S, Brassart B. Da Silva J, et al. Among authors: dukic s. Oncotarget. 2018 Apr 3;9(25):17839-17857. doi: 10.18632/oncotarget.24894. eCollection 2018 Apr 3. Oncotarget. 2018. PMID: 29707150 Free PMC article.
71 results